192 related articles for article (PubMed ID: 22781716)
21. Flow cytometric detection of aneuploid CD38(++) plasmacells and CD19(+) B-lymphocytes in bone marrow, peripheral blood and PBSC harvest in multiple myeloma patients.
Santonocito AM; Consoli U; Bagnato S; Milone G; Palumbo GA; Di Raimondo F; Stagno F; Guglielmo P; Giustolisi R
Leuk Res; 2004 May; 28(5):469-77. PubMed ID: 15068900
[TBL] [Abstract][Full Text] [Related]
22. Opposite activation of the Hedgehog pathway in CD138+ plasma cells and CD138-CD19+ B cells identifies two subgroups of patients with multiple myeloma and different prognosis.
Martello M; Remondini D; Borsi E; Santacroce B; Procacci M; Pezzi A; Dico FA; Martinelli G; Zamagni E; Tacchetti P; Pantani L; Testoni N; Marzocchi G; Rocchi S; Zannetti BA; Mancuso K; Cavo M; Terragna C
Leukemia; 2016 Sep; 30(9):1869-76. PubMed ID: 27074969
[TBL] [Abstract][Full Text] [Related]
23. Tumor-primed natural killer cells from patients with multiple myeloma lyse autologous, NK-resistant, bone marrow-derived malignant plasma cells.
Katodritou E; Terpos E; North J; Kottaridis P; Verrou E; Gastari V; Chadjiaggelidou C; Sivakumaran S; Jide-Banwo S; Tsirogianni M; Kapetanos D; Zervas K; Lowdell MW
Am J Hematol; 2011 Dec; 86(12):967-73. PubMed ID: 21919039
[TBL] [Abstract][Full Text] [Related]
24. The sensitivity of CD138 immunostaining of bone marrow trephine specimens for quantifying marrow involvement in MGUS and myeloma, including samples with a low percentage of plasma cells.
Ng AP; Wei A; Bhurani D; Chapple P; Feleppa F; Juneja S
Haematologica; 2006 Jul; 91(7):972-5. PubMed ID: 16818287
[TBL] [Abstract][Full Text] [Related]
25. Expression of the hematopoietic stem cell antigen CD34 on blood and bone marrow monoclonal plasma cells from patients with multiple myeloma.
Kimlinger T; Witzig TE
Bone Marrow Transplant; 1997 Mar; 19(6):553-6. PubMed ID: 9085734
[TBL] [Abstract][Full Text] [Related]
26. Syndecan-1 (CD138) immunoreactivity in bone marrow biopsies of multiple myeloma: shed syndecan-1 accumulates in fibrotic regions.
Bayer-Garner IB; Sanderson RD; Dhodapkar MV; Owens RB; Wilson CS
Mod Pathol; 2001 Oct; 14(10):1052-8. PubMed ID: 11598177
[TBL] [Abstract][Full Text] [Related]
27. Impact of CD138 Magnetic Bead-based Positive Selection on Bone Marrow Plasma Cell Surface Markers.
Bansal R; Kimlinger T; Gyotoku KA; Smith M; Rajkumar V; Kumar S
Clin Lymphoma Myeloma Leuk; 2021 Jan; 21(1):e48-e51. PubMed ID: 32873534
[TBL] [Abstract][Full Text] [Related]
28. [The Significance of CD319 and CD269 in the Detection of Immunophenotyping and Minimal Residual Disease in Multiple Myeloma Patients].
Chu B; Wang YT; Lu MQ; Shi L; Gao S; Fang LJ; Xiang QQ; Bao L
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2021 Aug; 29(4):1195-1202. PubMed ID: 34362502
[TBL] [Abstract][Full Text] [Related]
29. [Significance of CD138/syndecan-1 for multiple myeloma immunophenotypes].
Zhuang JL; Wang X; Wu YJ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2005 Dec; 13(6):1023-7. PubMed ID: 16403272
[TBL] [Abstract][Full Text] [Related]
30. Characterisation and relevance of CD138-negative plasma cells in plasma cell myeloma.
Reid S; Yang S; Brown R; Kabani K; Aklilu E; Ho PJ; Woodland N; Joshua D
Int J Lab Hematol; 2010 Dec; 32(6 Pt 1):e190-6. PubMed ID: 20201998
[TBL] [Abstract][Full Text] [Related]
31. Flow cytometric immunophenotypic analysis of 306 cases of multiple myeloma.
Lin P; Owens R; Tricot G; Wilson CS
Am J Clin Pathol; 2004 Apr; 121(4):482-8. PubMed ID: 15080299
[TBL] [Abstract][Full Text] [Related]
32. Increased circulating plasma cells detected by flow cytometry predicts poor prognosis in patients with plasma cell myeloma.
Bae MH; Park CJ; Kim BH; Cho YU; Jang S; Lee DH; Seo EJ; Yoon DH; Lee JH; Suh C
Cytometry B Clin Cytom; 2018 May; 94(3):493-499. PubMed ID: 29220877
[TBL] [Abstract][Full Text] [Related]
33. [Comparison and analysis of minimal residual disease in multiple myeloma patients detected by 4-color and 8-color fluorescence antibody panels].
Wang YZ; Lu J; Hao L; Chang Y; He LL; Huang XJ; Liu YR
Zhonghua Xue Ye Xue Za Zhi; 2017 Apr; 38(4):272-278. PubMed ID: 28468086
[No Abstract] [Full Text] [Related]
34. The potential diagnostic power of CD138+ microparticles from the plasma analysis for multiple myeloma clinical monitoring.
Liu ZY; Tian MY; Deng L; Wang YS; Xing R; Liu H; Fu R
Hematol Oncol; 2019 Oct; 37(4):401-408. PubMed ID: 31291481
[TBL] [Abstract][Full Text] [Related]
35. [Importance of determining the propidium-iodide index of plasmacytes in multiple myeloma. I. Relation to selected laboratory indicators of the disease].
Scudla V; Ordeltová M; Spidlová A; Bacovský J; Kurasová J; Vránová M
Vnitr Lek; 1999 Jun; 45(6):331-5. PubMed ID: 11045167
[TBL] [Abstract][Full Text] [Related]
36. CD138/syndecan-1: a useful immunohistochemical marker of normal and neoplastic plasma cells on routine trephine bone marrow biopsies.
Chilosi M; Adami F; Lestani M; Montagna L; Cimarosto L; Semenzato G; Pizzolo G; Menestrina F
Mod Pathol; 1999 Dec; 12(12):1101-6. PubMed ID: 10619261
[TBL] [Abstract][Full Text] [Related]
37. Immunophenotyping of plasma cells.
Rawstron AC
Curr Protoc Cytom; 2006 May; Chapter 6():Unit6.23. PubMed ID: 18770841
[TBL] [Abstract][Full Text] [Related]
38. [CD200 protein, bad prognostic in patients with multiple myeloma].
Vela-Ojeda J; García-Ruiz Esparza MA; Padilla-González Y; Pérez-Retiguin F; Reyes-Maldonado E; Maillet D; Montiel-Cervantes LA
Rev Med Inst Mex Seguro Soc; 2015; 53(4):438-43. PubMed ID: 26177431
[TBL] [Abstract][Full Text] [Related]
39. Syndecan-1 in multiple myeloma: relationship to conventional prognostic factors.
Aref S; Goda T; El-Sherbiny M
Hematology; 2003 Aug; 8(4):221-8. PubMed ID: 12911939
[TBL] [Abstract][Full Text] [Related]
40. Application of an immune-magnetic cell sorting method for CD138-positive plasma cells in FISH analysis of multiple myeloma.
Shin SY; Jang S; Park CJ; Chi HS; Lee JH; Lee JH; Lee KH; Suh C; Lim SE; Seo EJ
Int J Lab Hematol; 2012 Oct; 34(5):541-6. PubMed ID: 22672327
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]